Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1088

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 1088
---
 those
of our stockholders.

EQUITY PLAN INFORMATION

    Plan Category: 
    Number
    of securities to be issued upon exercise or issuance of outstanding options, units, warrants and
    rights(1):  
    Weighted
    average exercise price of outstanding options,  warrants and rights(1) :  
    Number
    of securities remaining available for future issuance(1): 
  
    2022 Equity Incentive Plan: 

    Equity compensation plans approved by security holders 
     4,437  
    $116.07  
     154,392 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 
  
    Total 
     4,437  
    $116.07  
     154,392 

    (1)
    Balances
    presented as of December 31, 2024

45

Purchases of Equity Securities by the Issuer
and Affiliated Purchasers

None.

Item 6. [Reserved]

Not applicable.

Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations

Prospective investors should read the following
discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes
and other financial information included elsewhere in this annual report. Some of the information contained in this discussion and analysis
or set forth elsewhere in this annual report, including information with respect to our plans and strategy for our business, includes
forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.”
This discussion should be read in conjunction with our audited consolidated financial statements and the notes thereto included elsewhere
in this report. In this discussion, we may use certain non-generally accepted accounting principles (GAAP) financial measures. An explanation
of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measures are included in this
“Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Investors should not consider
non-GAAP financial measures in isolation or as substitutes for financial information presented in compliance with GAAP.

1. Overview

We are a specialty pharmaceutical company with
a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention
and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda® (“Arakoda”),